Wedbush Reiterates “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS)

Wedbush reissued their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note released on Tuesday,RTT News reports. Wedbush currently has a $25.00 price objective on the stock. Wedbush also issued estimates for iTeos Therapeutics’ Q4 2024 earnings at ($0.95) EPS, FY2024 earnings at ($3.26) EPS, Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.56) EPS, FY2026 earnings at ($5.26) EPS, FY2027 earnings at ($4.54) EPS and FY2028 earnings at ($1.26) EPS.

ITOS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Monday, September 16th. Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a report on Monday, August 12th.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $8.23 on Tuesday. iTeos Therapeutics has a one year low of $7.99 and a one year high of $18.75. The company’s fifty day moving average price is $10.27 and its two-hundred day moving average price is $13.97. The company has a market capitalization of $300.64 million, a price-to-earnings ratio of -2.61 and a beta of 1.39.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ITOS. Candriam S.C.A. acquired a new position in iTeos Therapeutics during the 2nd quarter valued at $7,558,000. Acadian Asset Management LLC bought a new position in shares of iTeos Therapeutics during the 1st quarter worth about $3,337,000. State Street Corp raised its position in shares of iTeos Therapeutics by 21.9% during the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after buying an additional 211,452 shares during the last quarter. Clearline Capital LP acquired a new position in shares of iTeos Therapeutics during the second quarter valued at about $2,328,000. Finally, Kennedy Capital Management LLC bought a new stake in shares of iTeos Therapeutics in the first quarter valued at about $1,988,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.